BI Asset Management Fondsmaeglerselskab A S Boosts Position in DaVita Inc. $DVA

BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of DaVita Inc. (NYSE:DVA) by 63.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 86,000 shares of the company’s stock after acquiring an additional 33,394 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in DaVita were worth $9,770,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Invesco Ltd. grew its holdings in DaVita by 2.0% during the third quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares during the period. Dimensional Fund Advisors LP grew its holdings in DaVita by 8.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock valued at $144,230,000 after purchasing an additional 88,061 shares during the period. LSV Asset Management grew its holdings in DaVita by 1.1% during the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock valued at $106,426,000 after purchasing an additional 9,739 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in DaVita by 109.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after purchasing an additional 289,725 shares during the period. Finally, Neuberger Berman Group LLC grew its holdings in DaVita by 138.5% during the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after purchasing an additional 269,015 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Up 0.1%

NYSE DVA opened at $192.28 on Friday. The firm has a market cap of $12.34 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 0.63 and a beta of 0.91. The business has a 50-day moving average price of $171.47 and a 200-day moving average price of $143.18. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $202.69.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts expect that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DVA shares. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Barclays boosted their price target on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and boosted their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. UBS Group upped their price objective on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Truist Financial upped their price objective on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $199.17.

Insider Activity at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.